Crohn's Disease: Global Drug Forecast and Market Analysis to 2026 - Launch of Non-Anti-TNF Therapies Will Fuel CD Market Growth - ResearchAndMarkets.com

DUBLIN--()--The "PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.

In 2016, it is estimated that the global CD market was valued at over US$9 billion across the 7MM. By the end of the forecast period in 2026, sales across these markets will have grown steadily to reach almost US$13.5 billion, representing a Compound Annual Growth Rate (CAGR) of around 3.8% over the 10-year timeframe, which includes six new market entrants and the launch of biosimilars.

Major growth drivers in the CD market over the forecast period include:

  • The anticipated launches of interleukin (IL) inhibitors and anti-integrin therapies, including AbbVie's risankizumab, Genentech's etrolizumab, and Takeda's subcutaneous Entyvio (Entyvio SC), as well as Galapagos/Gilead's filgotinib, Celgene's mongersen sodium, and Shire's SHP-647, will provide more treatment options for physicians to choose from.
  • The number of diagnosed prevalent CD cases will increase to over 1.8 million in 2026 at an annual growth rate (AGR) of 2.3%. Total treated cases will grow to almost 1.2 million at an AGR of 2.3% during the 10-year period of 2016-2026.
  • Strong uptake of J&J's IL-12/23 inhibitor Stelarawill continue, generating sales of about US$1.2 billion across the 7MM in 2026.
  • The high unmet need for improved medical management of perianal fistulas presents an untapped market opportunity.

Summary

  • Launch of Non-Anti-TNF Therapies Will Fuel CD Market Growth to 2026
  • R&D and Corporate Strategies Will Be Focused on the Competitive Biologics Space
  • A Number of Clinical Unmet Needs Exist in the CD Treatment Realm
  • Treatments for the Management of Perianal Fistulas Remain Elusive
  • Novel Biologics and Biosimilars Will Reshape the CD Competitive Landscape
  • What Do Physicians Think?

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 Introduction

4 Disease Overview

5 Epidemiology

6 Disease Management

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

Companies Mentioned

  • Johnson & Johnson
  • AbbVie
  • UCB
  • Takeda
  • Roche
  • Celgene
  • Galapagos
  • Shire

For more information about this report visit https://www.researchandmarkets.com/research/fc8c8f/crohns_disease?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs